Last $1.32 USD
Change Today +0.01 / 0.76%
Volume 1.3M
LXRX On Other Exchanges
Symbol
Exchange
LXRX is not on other exchanges.
As of 8:10 PM 10/20/14 All times are local (Market data is delayed by at least 15 minutes).

lexicon pharmaceuticals inc (LXRX) Snapshot

Open
$1.29
Previous Close
$1.31
Day High
$1.32
Day Low
$1.26
52 Week High
10/21/13 - $2.62
52 Week Low
10/14/14 - $1.04
Market Cap
679.6M
Average Volume 10 Days
1.1M
EPS TTM
$-0.19
Shares Outstanding
514.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for LEXICON PHARMACEUTICALS INC (LXRX)

Related News

No related news articles were found.

lexicon pharmaceuticals inc (LXRX) Related Businessweek News

No Related Businessweek News Found

lexicon pharmaceuticals inc (LXRX) Details

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for human disease. Its drug development programs include LX4211, an orally-delivered small molecule compound that has completed two Phase II clinical trials for the treatment of type 2 diabetes patients, as well as an additional clinical trial for the treatment of type 2 diabetes patients with renal impairment; and completing a Phase II clinical trial for the treatment of type 1 diabetes patients. The company also develops telotristat etiprate or LX1032, an orally-delivered small molecule drug candidate, which has completed two Phase II clinical trials and is in a pivotal Phase III clinical trial for the treatment of carcinoid syndrome and ulcerative colitis. In addition, it develops LX1033, an orally-delivered small molecule compound that has completed Phase II clinical trial for the treatment of irritable bowel syndrome; LX2931, an orally-delivered small molecule compound, which has completed Phase II clinical trial for the treatment of rheumatoid arthritis; and LX7101, a topically-delivered small molecule compound that has completed Phase 1 clinical trial for the treatment of glaucoma. Further, the company’s preclinical development programs comprise LX2761, an orally-delivered small molecule compound for the treatment of diabetes. It has drug discovery and development collaborations with Bristol-Myers Squibb Company, Genentech, Inc., and Takeda Pharmaceutical Company Limited. Lexicon Pharmaceuticals, Inc. was founded in 1995 and is headquartered in The Woodlands, Texas.

149 Employees
Last Reported Date: 03/7/14
Founded in 1995

lexicon pharmaceuticals inc (LXRX) Top Compensated Officers

Co-Founder, Chief Scientific Officer and Exec...
Total Annual Compensation: $406.7K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $391.7K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $370.0K
Executive Vice President of Pharmaceutical Re...
Total Annual Compensation: $355.8K
Compensation as of Fiscal Year 2013.

lexicon pharmaceuticals inc (LXRX) Key Developments

Lexicon Pharmaceuticals Seeks Acquisitions

Lexicon Pharmaceuticals, Inc. (NasdaqGS:LXRX) will expend the net proceed from the sale of securities carried on August 29, 2014 for working capital purposes, investments or acquisitions. The company plans to invest in businesses, products and technologies that are complementary its business. The management will retain broad discretion in the allocation of the net proceeds.

Lexicon Pharmaceuticals, Inc. Provides Cash Flow Guidance for the Year 2014

Lexicon Pharmaceuticals, Inc. provided cash flow guidance for the year 2014. The company expects net cash used in operations to be in the range of $87 million to $92 million in the year 2014.

Lexicon Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

Lexicon Pharmaceuticals, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, total revenues increased to $0.7 million from $0.2 million for the corresponding period in 2013, primarily due to revenues recognized from a collaboration with a non-profit institute supporting the Phase 2 development of LX4211 in type 1 diabetes and increased revenues from other functional genomics activities. Net loss was $26.0 million, or $0.05 per share, compared to a net loss of $29.1 million, or $0.06 per share, in the corresponding period in 2013. For the three and six months ended June 30, 2014, net loss included non-cash, stock-based compensation expense of $1.8 million and $4.1 million, respectively. Loss from operations was $26.11 million compared to $28.62 million a year ago. For the six months, total revenues increased 66% to $1.0 million from $0.6 million for the corresponding period in 2013. Net loss was $56.9 million, or $0.11 per share, compared to a net loss of $55.1 million, or $0.11 per share, for the corresponding period in 2013. For the three and six months ended June 30, 2013, net loss included non-cash, stock-based compensation expense of $1.9 million and $4.0 million, respectively. Loss from operations was $56.58 million compared to $54.18 million a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LXRX:US $1.32 USD +0.01

LXRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $41.46 USD +0.60
Boston Scientific Corp $11.61 USD +0.24
CR Bard Inc $146.72 USD +1.45
Johnson & Johnson $99.20 USD +0.50
Medtronic Inc $63.84 USD +1.85
View Industry Companies
 

Industry Analysis

LXRX

Industry Average

Valuation LXRX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 259.2x
Price/Book 5.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 221.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LEXICON PHARMACEUTICALS INC, please visit www.lexpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.